Condition: Chronic Myeloid Leukemia (CML) · Sponsor: Versailles Hospital
Single-center study, prospective, phase II trial. The study objectives are : * To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI discontinuation. * To assess survival without loss of MMR over a 12 months period following a second TKI discontinuation in subjects who achieve or maintain \< MR4.5 with the combination PIO and TKI administered for at least 6 months.
This description comes directly from the study's public registry record.
Sandrine Roux, MC · +33139239777 · sroux@ght78sud.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de Versailles | Le Chesnay, France | Recruiting |
| Hôpital Bicêtre | Le Kremlin-Bicêtre, France | Withdrawn |
| CHU Lyon | Lyon, France | Recruiting |
| CHU de Nantes | Nantes, France | Withdrawn |
| CHU de Rennes | Rennes, France | Withdrawn |
| IUCT | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02889003